Effective anticoagulation for a percutaneous ventricular assist device using a heparin-based purge solution

Area of Science:

• Cardiology
• Biomedical Engineering
• Pharmacology

Background:

• Cardiogenic shock necessitates advanced circulatory support, such as the Impella device.
• Effective anticoagulation is crucial for patients on mechanical circulatory support to prevent thrombotic complications.

Observation:

• A novel anticoagulation protocol was implemented in four patients requiring Impella support for cardiogenic shock.
• The protocol integrated a heparin-based purge solution into the total hourly heparin dosage.
• Despite prolonged support and frequent adjustments by the Automated Impella Controller, patients maintained stable anticoagulation (aPTT).

Findings:

• All four patients survived to hospital discharge without significant bleeding or thromboembolic events.
• No device malfunctions or pump clotting occurred during support.
• The protocol successfully managed anticoagulation in patients with cardiogenic shock, including those with myocardial infarction and severe aortic valvular disease.

Implications:

• This novel heparin protocol offers a safe and effective anticoagulation strategy for Impella device use.
• Standardizing anticoagulation protocols that account for purge solution heparin is vital for optimizing patient outcomes.
• This approach may reduce the risk of complications and improve survival in critically ill patients requiring mechanical circulatory support.